Dyadic International (NASDAQ:DYAI) Stock Price Crosses Below 50 Day Moving Average of $1.47

Shares of Dyadic International, Inc. (NASDAQ:DYAIGet Free Report) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.47 and traded as low as $1.35. Dyadic International shares last traded at $1.39, with a volume of 6,355 shares.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Dyadic International in a research report on Monday, November 13th.

Get Our Latest Stock Report on Dyadic International

Dyadic International Trading Down 2.1 %

The company has a market cap of $40.05 million, a price-to-earnings ratio of -6.04 and a beta of 0.63. The stock has a 50-day simple moving average of $1.47 and a 200-day simple moving average of $1.67.

Institutional Trading of Dyadic International

Several institutional investors have recently modified their holdings of DYAI. Charles Schwab Investment Management Inc. acquired a new stake in shares of Dyadic International in the second quarter valued at $32,000. Captrust Financial Advisors acquired a new stake in shares of Dyadic International in the first quarter valued at $45,000. Atria Wealth Solutions Inc. acquired a new stake in shares of Dyadic International in the third quarter valued at $46,000. Vanguard Group Inc. lifted its holdings in shares of Dyadic International by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 803,917 shares of the biotechnology company’s stock valued at $1,294,000 after buying an additional 21,003 shares during the period. Finally, Chapin Davis Inc. raised its position in shares of Dyadic International by 1.1% during the second quarter. Chapin Davis Inc. now owns 832,301 shares of the biotechnology company’s stock worth $1,606,000 after purchasing an additional 9,000 shares during the period. Institutional investors and hedge funds own 15.58% of the company’s stock.

About Dyadic International

(Get Free Report)

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.

Featured Articles

Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.